153 related articles for article (PubMed ID: 10891907)
1. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS.
Saindane AM; Ge Y; Udupa JK; Babb JS; Mannon LJ; Grossman RI
Neurology; 2000 Jul; 55(1):61-5. PubMed ID: 10891907
[TBL] [Abstract][Full Text] [Related]
2. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
[TBL] [Abstract][Full Text] [Related]
4. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans-Coutinho M; Clanet M; Radue EW; Kappos L;
Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
[TBL] [Abstract][Full Text] [Related]
5. Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
Chard DT; Griffin CM; Parker GJ; Kapoor R; Thompson AJ; Miller DH
Brain; 2002 Feb; 125(Pt 2):327-37. PubMed ID: 11844733
[TBL] [Abstract][Full Text] [Related]
6. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
7. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
8. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.
Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
Neurology; 2005 Mar; 64(6):1001-7. PubMed ID: 15781816
[TBL] [Abstract][Full Text] [Related]
9. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
Oreja-Guevara C; Rovaris M; Iannucci G; Valsasina P; Caputo D; Cavarretta R; Sormani MP; Ferrante P; Comi G; Filippi M
Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
[TBL] [Abstract][Full Text] [Related]
10. A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.
Zivadinov R; Horakova D; Bergsland N; Hagemeier J; Ramasamy DP; Uher T; Vaneckova M; Havrdova E; Dwyer MG
AJNR Am J Neuroradiol; 2019 Mar; 40(3):446-452. PubMed ID: 30819766
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis.
Luks TL; Goodkin DE; Nelson SJ; Majumdar S; Bacchetti P; Portnoy D; Sloan R
Mult Scler; 2000 Oct; 6(5):332-7. PubMed ID: 11064443
[TBL] [Abstract][Full Text] [Related]
12. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
[TBL] [Abstract][Full Text] [Related]
14. Normalized regional brain atrophy measurements in multiple sclerosis.
Zivadinov R; Locatelli L; Stival B; Bratina A; Grop A; Nasuelli D; Brnabic-Razmilic O; Zorzon M
Neuroradiology; 2003 Nov; 45(11):793-8. PubMed ID: 14551760
[TBL] [Abstract][Full Text] [Related]
15. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
16. Impact of individual cognitive profile on visuo-motor reorganization in relapsing-remitting multiple sclerosis.
Gioia MC; Cerasa A; Liguori M; Passamonti L; Condino F; Vercillo L; Valentino P; Clodomiro A; Quattrone A; Fera F
Brain Res; 2007 Sep; 1167():71-9. PubMed ID: 17689504
[TBL] [Abstract][Full Text] [Related]
17. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
[TBL] [Abstract][Full Text] [Related]
18. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
19. Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study.
Rashid W; Davies GR; Chard DT; Griffin CM; Altmann DR; Thompson AJ; Miller DH
Mult Scler; 2007 Mar; 13(2):178-85. PubMed ID: 17439882
[TBL] [Abstract][Full Text] [Related]
20. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
